Author Archives: Patricia Inacio, PhD

PH-HFpEF Patients Show Initial Response to Levosimendan in HELP Trial, Data Show

Preliminary data from the Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) patients with heart failure and preserved ejection fraction (PH-HFpEF) showed that 86% of those analyzed responded to the therapy, with less pressure evident on heart’s left atrium. The ongoing trial’s predefined response criterion — the…

Prerequisite Response Achieved in 83% of Patients After Levosimendan Infusion in HELP Trial

Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy is a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF). The response…

Opsumit-Adcirca Combo Improves Blood Flow and Physical Capacity in People New to PAH, Trial Data Show

A combination of Opsumit (macitentan) plus Adcirca (tadalafil) lowered pulmonary vascular resistance — a measure showing how well blood flows through vessels — by 47% in people newly diagnosed with pulmonary arterial hypertension (PAH) and improved their physical capacity, new data show. Olivier Sitbon, MD, PhD, with Université Paris–Sud presented the…